SCHEMBL4415701

SCHEMBL4415701

O=S(=O)(Cc1ccccc1)N1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
GAA P10253 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ALOX15 P16050 2/20 0.41
MAPK1 P28482 2/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
MAOB P27338 2/20 0.41
KMT2A Q03164 1/20 0.40
HTT P42858 2/20 0.39
DGAT1 O75907 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552000 0.93 GAA (0.46) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL4417947 0.91 P2RX3 (0.40) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL2182100 0.89 LDHA (0.44) SMN1; SMN2ALDH1A1LMNANPC1RAB9A
SCHEMBL4414076 0.89 ALDH1A1 (0.41) MAPTALDH1A1LMNANPC1RAB9A
SCHEMBL4427710 0.84 NPC1 (0.45) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL4415696 0.84 MAPT (0.55) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL4418890 0.84 MEN1 (0.47) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL4419245 0.84 NPC1 (0.46) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL2181891 0.82 POLB (0.46) MAPTSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL4413651 0.82 NPC1 (0.42) MAPTSMN1; SMN2ALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAPT 1368/4885SMN1; SMN2 4003/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.